Hindawi Oxidative Medicine and Cellular Longevity Volume 2017, Article ID 1913954, 1 page https://doi.org/10.1155/2017/1913954



## Corrigendum

## Corrigendum to "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E<sub>2</sub> Receptor EP4 Pathway"

Yu Ah Hong,<sup>1</sup> Keum Jin Yang,<sup>2</sup> So Young Jung,<sup>2</sup> Ki Cheol Park,<sup>2</sup> Hyunsu Choi,<sup>2</sup> Jeong Min Oh,<sup>2</sup> Sang Ju Lee,<sup>1</sup> Yoon Kyung Chang,<sup>1</sup> Cheol WheePark,<sup>1</sup> Chul Woo Yang,<sup>1</sup> Suk Young Kim,<sup>1</sup> and Hyeon Seok Hwang<sup>1</sup>

Correspondence should be addressed to Hyeon Seok Hwang; hwanghs@catholic.ac.kr

Received 6 June 2017; Accepted 2 July 2017; Published 13 August 2017

Copyright © 2017 Yu Ah Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin  $\rm E_2$  Receptor EP4 Pathway" [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).


## Reference


[1] Y. A. Hong, K. J. Yang, S. Y. Jung et al., "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E<sub>2</sub> Receptor EP4 Pathway," Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 5031926, 17 pages, 2017.

<sup>&</sup>lt;sup>1</sup>Division of Nephrology, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea


<sup>&</sup>lt;sup>2</sup>Clinical Research Institute, Daejeon St. Mary's Hospital, Daejeon, Republic of Korea

















Submit your manuscripts at https://www.hindawi.com



